03 February 2025
03 February 2025
The oversubscribed Series C round was led by US digital health investors Transformation Capital.
Both existing and pipeline products will be supported by the new facility.
Median Technologies now plans to submit its lung cancer diagnostic for regulatory clearance in the US and EU in the coming months.
The partnership is set to enhance survival rates and quality of life by integrating imaging technologies into cardiac care.
The software was found to improve CHD detection by more than 15% and provide conclusions in 98.8% of exams.
The DOD funding will facilitate a three-year clinical trial in partnership with the University of Texas Health Science Center.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
